Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372638 | 1.00 | CHRM5 (0.39) | CHRM5ADRA2CKDM4ETDP1ACHE | |
| SCHEMBL372637 | 1.00 | CHRM5 (0.39) | CHRM5ADRA2CKDM4ETDP1ACHE | |
| Hydrochloric Acid SCHEMBL3487702 | 0.98 | CHRM5 (0.38) | CHRM5ADRA2CKDM4ETDP1ACHE | |
| Hydrochloric Acid SCHEMBL19002911 | 0.98 | CHRM5 (0.38) | CHRM5ADRA2CKDM4ETDP1ACHE | |
| Hydrochloric Acid SCHEMBL19002912 | 0.98 | CHRM5 (0.38) | CHRM5ADRA2CKDM4ETDP1ACHE | |
| Hydrochloric Acid SCHEMBL3487703 | 0.98 | CHRM5 (0.38) | CHRM5ADRA2CKDM4ETDP1ACHE | |
| SCHEMBL1204165 | 0.93 | CHRM5 (0.42) | CHRM5ADRA2CKDM4ETDP1ACHE | |
| SCHEMBL24474498 | 0.92 | CHRM5 (0.50) | CHRM5ADRA2CKDM4ETDP1ACHE | |
| SCHEMBL30697248 | 0.92 | CHRM5 (0.50) | CHRM5ADRA2CKDM4ETDP1ACHE | |
| SCHEMBL22570086 | 0.91 | CHRM5 (0.53) | CHRM5ADRA2CKDM4ETDP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560499-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-1778240-B1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3560499-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3560499-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| EP-2481739-B1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO LTD (CN) | 2016-12-14 | — | — | EP | disclosed |
| CN-1745081-A | Dihydropteridinones, method for the production thereof and use thereof as pharmaceutical preparations | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-03-08 | — | — | CN | disclosed |
| WO-2006018221-A1 | DIHYDROPTERIDINONE INFUSION SOLUTION HAVING A LONG SHELF LIFE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018185-A2 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| US-20060025411-A1 | Methods for treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-02-02 | — | — | US | disclosed |
| EP-1599478-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6861422-B2 | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-20 | — | — | US | disclosed |
| WO-2004076454-A1 | DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | CHRM5 4882/4885ADRA2C 4790/4885KDM4E 2045/4885 |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | CHRM5 2245/4885ADRA2C 1306/4885KDM4E 4832/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | CHRM5 4882/4885ADRA2C 4790/4885KDM4E 2045/4885 |
| US-20040176380-A1 | New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions | QDPR, DHPS, DRD5 | CHRM5 2219/4885ADRA2C 834/4885KDM4E 4006/4885 |
| US-20050014760-A1 | Methods of treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | CHRM5 1881/4885ADRA2C 1124/4885KDM4E 4721/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | CHRM5 4872/4885ADRA2C 4161/4885KDM4E 1307/4885 |
| US-20060025411-A1 | Methods for treating diseases or conditions using dihydropteridinone compounds | QDPR, DHPS, DHFR | CHRM5 1855/4885ADRA2C 970/4885KDM4E 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.